PLA2G7 and hepatocellular carcinoma: By pharmacologically inhibiting PLA2G7 in vivo or by co-culture in vitro, PLA2G7 inhibition via darapladib promoted NF-κB pathway-mediated M1 TAM infiltration and sensitized HCC cells to ICB therapy [83].